Neutrophils from chronic lymphocytic leukemia patients exhibit an increased capacity to release extracellular traps (NETs) by Podaza, Enrique Arturo et al.
1 3
Cancer Immunol Immunother (2017) 66:77–89
DOI 10.1007/s00262-016-1921-7
ORIGINAL ARTICLE
Neutrophils from chronic lymphocytic leukemia patients exhibit 
an increased capacity to release extracellular traps (NETs)
Enrique Podaza1 · Florencia Sabbione2 · Denise Risnik1 · Mercedes Borge1 · 
María B. Almejún1 · Ana Colado1 · Horacio Fernández‑Grecco3 · María Cabrejo3 · 
Raimundo F. Bezares4 · Analía Trevani2 · Romina Gamberale1 · Mirta Giordano1 
Received: 16 February 2016 / Accepted: 23 October 2016 / Published online: 28 October 2016 
© Springer-Verlag Berlin Heidelberg 2016
its depletion reduced plasma capacity to enhance NETs 
release. Finally, we found that culture with NETs delayed 
spontaneous apoptosis and increased the expression of acti-
vation markers on leukemic B cells. Our study provides 
new insights into the immune dysregulation in CLL and 
suggests that the chronic inflammatory environment typi-
cal of CLL probably underlies this inappropriate neutrophil 
priming.
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Abbreviations
CLL  Chronic lymphocytic leukemia
DHR  Dihydrorhodamine 123
DPI  Diphenyleneiodonium chloride
FSC  Forward scatter
HD  Healthy donors
MNase  Micrococcal nuclease
MPO  Myeloperoxidase
NETs  Neutrophil extracellular traps
PFA  Paraformaldehyde
PI  Propidium iodide
ROS  Reactive oxygen species
TMB  3,3′,5,5′ tetramethylbenzidine
Introduction
Chronic lymphocytic leukemia (CLL) is characterized by 
the progressive accumulation of clonal CD5+ B cells in 
lymphoid tissues, bone marrow and blood [1]. The clini-
cal course of CLL is highly heterogeneous, ranging from 
an indolent disease that will not require treatment for many 
Abstract Chronic lymphocytic leukemia (CLL) is char-
acterized by immune defects that contribute to a high rate 
of infections and autoimmune cytopenias. Neutrophils are 
the first line of innate immunity and respond to pathogens 
through multiple mechanisms, including the release of neu-
trophil extracellular traps (NETs). These web-like struc-
tures composed of DNA, histones, and granular proteins are 
also produced under sterile conditions and play important 
roles in thrombosis and autoimmune disorders. Here we 
show that neutrophils from CLL patients are more prone to 
release NETs compared to those from age-matched healthy 
donors (HD). Increased generation of NETs was not due 
to higher levels of elastase, myeloperoxidase, or reactive 
oxygen species production. Instead, we found that plasma 
from CLL patients was able to prime neutrophils from 
HD to generate higher amounts of NETs upon activation. 
Plasmatic IL-8 was involved in the priming effect since 
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years to a rapid progression and poor response to therapy 
[2]. A major feature of CLL is a profound immune dys-
regulation that worsens as the disease progresses and after 
antineoplastic therapy [3]. As a consequence, infectious 
complications are still the main cause of morbidity and 
mortality in CLL patients [4, 5]. On the other hand, the 
breakdown of tolerance to self-antigens leads to autoim-
mune cytopenias in up to 30% of CLL patients during the 
course of the disease [6]. Although the mechanisms respon-
sible for immune defects in CLL are not completely under-
stood, increasing evidence demonstrates that leukemic cells 
are able to impair acquired and innate immunity through 
the release of soluble factors and cell-to-cell contact [3]. 
Despite the specific reports of dysfunction in T cells [7], 
monocytes [8], macrophages [9], NK cells [10], and non-
leukemic B cells [11] in the context of CLL, little is known 
about neutrophils, the most abundant leukocyte population 
in peripheral blood.
Neutrophils constitute a first line of defense against 
invading pathogens [12]. They are recruited to sites of 
infection where they can destroy microorganisms using dif-
ferent strategies such as phagocytosis and degranulation. A 
newly discovered feature of the biology of neutrophils is 
their ability to release neutrophil extracellular traps (NETs) 
[13, 14]. Composed of a chromatin meshwork decorated 
with antimicrobial peptides and enzymes, NETs are gener-
ated through an active form of cell death known as NETosis 
[15]. Not only microorganisms but also a variety of soluble 
and particulate stimuli can trigger NETosis including high 
mobility group B1 (HMGB1) [16], TNFα [17] and choles-
terol crystals [18]. In fact, NETs can also be formed under 
sterile conditions and have been reported to play relevant 
roles in pathologies as diverse as thrombosis [19], systemic 
lupus erythematosus [20], diabetes [21] and cancer [22].
The aim of the present study was to evaluate the capac-
ity of neutrophils from CLL patients to generate NETs. 
Given the frequency of respiratory infections by capsulated 
bacteria in CLL patients [5] and the reported relevance of 
NETs to confine the pneumococcal infection and reduce its 
virulence [23], we hypothesized that the capacity to form 
NETs would be impaired in CLL patients. By contrast, we 
found that neutrophils from CLL patients are more prone to 
release NETs in vitro compared to HD and that these NETs 
might contribute to leukemic cells survival.
Materials and methods
Reagents
Culture medium (RPMI 1640) was purchased from Life 
Technologies (Grand Island, NY); FBS from Natocor 
(Argentina), penicillin and streptomycin from GIBCO 
Laboratories (Grand Island, NY) and Ficoll from GE 
Healthcare (Munich, Germany). Micrococcal nuclease 
(MNase) was from Worthington Biochemical (Lake-
wood, NJ). One-step Ultra TMB (3,3′,5,5′-tetramethylb-
enzidine) was from Thermo Fisher (Massachusetts, MA). 
Anti-human elastase Ab was obtained from Calbiochem 
(Massachusetts, MA), and rabbit total IgG and DyLight-
488-anti-rabbit were purchased from Jackson ImmunoRe-
search Laboratories (West Grove, PA). Dihydrorhodamine 
123 (DHR) and SYBRGold were from Life Technologies 
(Carlsbad, CA). TNFα was from R&D Systems (Minneap-
olis, MN), PE-anti-human CD69, FITC-anti-human CD80, 
and human IL-8 ELISA Kit were purchased from BD Bio-
sciences (Franklin Lakes, NJ). PCy5-anti-human CD19 
was obtained from Beckman-Coulter (Brea, CA). PE-anti-
human-CD86, FITC-anti-human CXCR1, PE-anti-human 
CXCR2, and recombinant IL-8 were from Biolegend (San 
Diego, CA). Aqua-Poly/mount coverslipping medium was 
purchased from Polysciences (Warrington, PA). Annexin-
V-FITC was obtained from ImmunoTools (Friesoythe, 
Germany). All other reagents were acquired from Sigma-
Aldrich (St. Louis, MO).
CLL patients and HD samples
Peripheral blood samples were obtained from CLL patients 
(age range 50–87), healthy age-matched and healthy young 
(age range 21–50) donors after informed consent in accord-
ance with the Declaration of Helsinki. These studies were 
approved by the Institutional Review Board of the Institutes 
of the National Academy of Medicine, Buenos Aires. At the 
time of the analysis patients were free from clinically rel-
evant infectious complications and were either untreated 
or had not received antineoplastic treatment for ≥3 months 
before the study began.
Cell separation procedures and culture
Peripheral blood leukocytes were isolated by centrifuga-
tion over a Ficoll–Triyosom layer. PBMC were recovered 
from the interface, washed twice with saline and sus-
pended in complete medium (RPMI 1640 supplemented 
with 10% FBS and antibiotics). Neutrophils were recov-
ered from the bottom pellet after dextran sedimentation 
and contaminating erythrocytes were removed by hypo-
tonic lysis as previously reported [24]. After washing with 
saline, cells (>96% viable neutrophils) were resuspended 
in RPMI 1640 without phenol red and supplemented with 
10% heat-inactivated FBS and antibiotics. To minimize 
neutrophil spontaneous activation, cells were used imme-
diately after isolation.
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NETs induction and quantification
To induce NETs formation, neutrophils (2 × 106 cells/ml) 
were seeded in 48-well plate and stimulated with PMA 
25 ng/ml during 4 h at 37 °C under a humidified atmos-
phere with 5% CO2. Alternatively, neutrophils were stim-
ulated with ionomycin (1 µM), TNFα (10 ng/ml), LPS 
(100 ng/ml), or IL-8 (0.15 or 10 ng/ml) as described in the 
corresponding figure legends. NETs-containing superna-
tants were recovered after treatment with low dose MNase 
(1 U/ml) to detach NETs from cell debris and 30 min later, 
EDTA (5 mM) was added to stop MNase reaction.
NETs were quantified by determining DNA concentra-
tion and elastase activity in supernatants. DNA was quan-
tified by SYBRGold (1:2000) staining and fluorometric 
detection (BioTeK Instruments, Winooski, VT, USA). DNA 
values were corrected by subtracting those obtained when 
the same sample was pretreated with a high concentration 
of MNase (10 U/ml) for 30 min to degrade DNA. Elastase 
activity in supernatants was assessed by spectrophotometry 
using the specific substrate N-methoxysuccinyl-Ala-Ala-
Pro-Val as described [25].
Analysis of the NETotic process by confocal microscopy
Visualization of NETs by confocal microscopy was 
performed using an adapted version of the protocol 
described by Brinkmann et al. [13]. Briefly, neutrophils 
(2 × 106 cells/ml) were seeded on poly-l-lysine-coated 
microscope slides and stimulated with PMA for 2–4 h. 
After incubation, the samples were fixed with 4% para-
formaldehyde (PFA), permeabilized with 0.5% Triton 
X-100 in PBS for 1 min and blocked with 5% heat-inac-
tivated FBS in PBS for 1 h. Then samples were incubated 
with rabbit anti-human elastase Ab (1 µg/ml) or the cor-
responding isotype control for 1 h, washed, and exposed 
to DyLight488-conjugated goat anti-rabbit IgG Ab for 
an additional hour. For DNA staining, samples were 
incubated with PI for 5 min and mounted using Aqua-
Poly/mount medium. Images were acquired by using a 
FluoView FV1000 confocal microscope (Olympus, Tokyo, 
Japan) equipped with a Plapon 60×/1.42 objective and 
analyzed with Olympus FV10-ASW software.
Analysis of ROS production
For measurement of intracellular ROS production, the fluo-
rescent dye DHR was used. Neutrophils from HD or CLL 
patients were stained by incubation with 2 µM DHR for 
30 min at 37 °C, washed once and exposed to PMA (25 ng/
ml) or saline. After 20 min of incubation, cells were placed 
on ice and immediately analyzed by flow cytometry.
Evaluation of elastase and MPO activity in neutrophils
Neutrophils (5 × 105) were lysed with PBS 1% Triton 
X-100 and centrifuged, and supernatants were collected for 
the immediate determination of enzyme activity. Elastase 
activity was measured as described above for quantification 
of NETs. Peroxidase activity was determined using TMB 
as substrate. Briefly, 25 µl of sample (increasing dilutions 
in PBS) was combined with 25 µl 1-Step TMB solution 
and incubated at 37 °C for 5 min. The reaction was stopped 
by adding 50 µl H2SO4 and absorbance was measured at 
450 nm.
Modulation of CLL‑B cell apoptosis and activation 
markers by incubation with NETs
PBMC (>93% leukemic B cells) from CLL patients were 
suspended in complete medium and placed into 48-well 
plates at a concentration of 2 × 106/ml. NETs were 
obtained by stimulating neutrophils with ionomycin for 
1 h, then cells were washed twice, and reincubated for an 
additional 3 h at 37 °C. Alternatively, neutrophils were 
stimulated with LPS (100 ng/ml) plus IL-8 (0.15 ng/ml). 
Supernatants containing NETs were recovered as described 
above except that mechanical disruption instead of MNase 
was used to separate NETs from cell debris. Supernatants 
were added to PBMC at 1:3 final dilutions. PBMC were 
cultured with or without NETs at 37 °C. The expression of 
surface activation markers were assessed on CD19+ CD5+ 
cells at 24 h (CD69), 48 h (CD86) or 72 h (CD80) by flow 
cytometry. These time points were chosen based on optimal 
measurements for each marker. Leukemic B cell viability 
was evaluated at 48 h by Annexin-V/PI staining and flow 
cytometry analysis.
Statistical analysis
Data were analyzed using Kruskal–Wallis test, Friedman 
test, Mann–Whitney test or Wilcoxon signed rank test. 
When appropriate, multiple comparisons Dunn’s posttest 
was used. For correlation analysis, nonparametric Spear-
man’s correlation coefficient was calculated. Data were 
analyzed using GraphPad Prism software version 6.01.
Results
Neutrophils from CLL patients release higher levels 
of NETs compared to HD
We first evaluated the capacity of circulating neutrophils 
from CLL patients to form NETs in vitro. To that aim, 
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purified neutrophils were stimulated with PMA, a potent 
NET inducer, for 4 h. NET formation was visualized by 
confocal microscopy by evaluating the colocalization of 
DNA with elastase (Fig. 1a) and quantified by measuring 
the concentration of DNA and the enzymatic activity of 
elastase in supernatants (Fig. 1b). Given that PMA-induced 
NETosis depends on the generation of ROS by NADPH 




























































































































Fig. 1  Neutrophils from CLL patients are more prone to release 
NETs compared to those from HD. a Neutrophils (2 × 106 cells/
ml) from CLL patients were incubated with PMA or medium (unst.) 
for 4 h. Preparations were stained with anti-neutrophil elastase Ab 
(green) and PI (red), and analyzed by confocal microscopy. Shown 
are representative fluorescence images (n = 5). Scale bar 25 μm. b 
Elastase activity and DNA concentration measured in supernatants of 
neutrophils from CLL patients stimulated or not with PMA. Where 
indicated, DPI (10 µM) was added 30 min before PMA to inhibit 
NADPH oxidase. Results are the mean ± SEM of 5 independent 
experiments. Significance was determined using Friedman test fol-
lowed by Dunn’s multiple comparison posttest. c Elastase activity and 
DNA concentration measured in supernatants of unstimulated (black 
dots) or PMA-stimulated (white dots) neutrophils. Individual val-
ues and mean for each condition are shown. d Comparison of NETs 
release induced by TNFα + LPS or Ionomycin. Significance was 
determined using Kruskal–Wallis test followed by Dunn’s multiple 
comparison posttest. *p < 0.05 unstimulated versus PMA-stimulated 
neutrophils. e Representative images of NETotic neutrophils showing 
co-localization of elastase and DNA (arrow heads). Scale bar 25 μm. 
The percentages of NETotic cells in HD and CLL samples are shown 
(mean ± SEM of 5 experiments). Significance was determined using 
Mann–Whitney test
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shown in Fig. 1b, inhibition of NADPH oxidase with DPI 
prevented NET formation.
Next, we compared the capacity of neutrophils from 
CLL patients and age-matched HD to form NETs. Clini-
cal features of CLL patients are summarized in supplemen-
tary Table 1. We found that neutrophils from CLL patients 
released significantly higher levels of NETs compared to 
those from HD (Fig. 1c). This increased response was also 
observed when stimulation was performed with the calcium 
ionophore ionomycin or by priming cells with TNFα fol-
lowed by LPS exposure (Fig. 1d).
For most stimuli, the release of NETs is the result of 
a unique form of cell death known as NETosis. During 
the process, the activated neutrophil first loses the clas-
sical lobulated nuclear morphology and later the inter-
nal membranes disappear allowing the mixing of nuclear, 
cytoplasm and granular components [26]. To corroborate 
the differences in NETs generation between neutrophils 
from HD and CLL patients, we evaluated the morphologi-
cal changes of PMA-activated neutrophils before the final 
phase of NETs extrusion. We found that at 120 min after 
PMA challenge a higher proportion of neutrophils from 
CLL patients showed colocalization of elastase and DNA 
in expanded nuclei characteristic of NETotic cells (Fig. 1e) 
and, as expected, they were no longer functional (supple-
mentary figure 1). Not only there were increased numbers 
of NETotic cells in CLL samples, but they also showed fea-
tures of a more advanced NETosis compared to those from 
age-matched HD.
Plasma from CLL patients increases the capacity 
of neutrophils from HD to release NETs
During the formation of NETs, neutrophil elastase trans-
locates from the granules to the nucleus via a mechanism 
that requires ROS and MPO [27]. In an attempt to deter-
mine whether differences in any of these molecules could 
account for the increased generation of NETs in CLL 
patients, we evaluated ROS production induced by PMA as 
well as elastase and MPO activities. As shown in Fig. 2a, 
there were no significant differences in any of these param-
eters between neutrophils from young or age-matched HD 
and CLL patients.
Since neutrophils can be primed by cytokines as IL-8 
or TNFα to become more susceptible to release NETs [28, 
29], and these and other soluble factors have been reported 
to be elevated in CLL [30], we decided to evaluate whether 
plasma from CLL patients could enhance NET formation. 
To that aim, neutrophils from young HD were incubated 
with plasma from CLL patients or age-matched HD for 
40 min, washed and suspended in fresh complete medium. 
Then neutrophils were stimulated with PMA (25 ng/ml) 
and cultured for an additional 3.5 h to allow the release 
of NETs. We found that exposure of neutrophils to CLL 
plasma significantly enhanced production of NETs induced 
by PMA while plasma from HD did not (Fig. 2b). None of 
the evaluated CLL plasma samples were able to stimulate 
NET release in the absence of PMA challenge (not shown). 
We corroborated the priming effect of CLL plasma on neu-
trophils by evaluating the early morphological changes that 
are characteristic of death by NETosis [26]. The propor-
tion of NETotic cells were significantly increased in cul-
tures exposed to CLL plasma compared to cells activated in 
medium alone (Fig. 2c). Together these results suggest that 
soluble factors present in CLL plasma might be responsible 
for priming neutrophils to release NETs.
IL‑8 depletion impairs the priming activity of CLL 
plasma to release NETs
Among the potential candidates in CLL plasma capable 
of favoring NETs production, we chose to explore the 
involvement of IL-8 because it has been implicated in 
NETs formation by different groups [17, 28] and, more 
importantly, its plasmatic levels are significantly increased 
in most CLL patients as we corroborated for our cohort 
(supplementary figure 2). To determine whether IL-8 
was responsible, at least in part, for the priming effect 
of CLL plasma on NETs release, we reduced its levels 
by incubating CLL plasma on anti-IL-8-coated plates 
for 60 min (Fig. 3a) and compared the capacity of whole 
and IL-8 depleted plasma to modulate NETs formation. 
The results show that the priming effect of CLL plasma 
on NETs release was markedly impaired after IL-8 deple-
tion (Fig. 3b). These findings prompted us to look for a 
correlation between the plasmatic levels of IL-8 in our 
CLL patient cohort and the capacity of their neutrophils 
to release NETs upon activation. We found that both, the 
activity of elastase and the amount of DNA released to 
supernatants after PMA challenge significantly correlated 
with the levels of IL-8 in plasma (Fig. 3c).
As it was reported that recombinant IL-8 is able to 
directly induce NETs formation but we found that CLL 
plasma did not stimulate NETs in the absence of PMA 
challenge, we performed additional experiments comparing 
two concentrations of IL-8 in their capacity to activate neu-
trophils for NETosis. In agreement with previous reports 
[17, 28], we found that 10 ng/ml of recombinant IL-8 
stimulated NETs release, while 0.15 ng/ml, the average 
concentration of IL-8 that we detected in CLL plasma had 
no effect, though it enhanced NETs formation induced by 
LPS (supplementary figure 3). Interestingly, when added to 
HD plasma, this low dose of recombinant IL-8 potentiated 
NETs release induced by PMA (Fig. 3d). Overall, these 
data suggest that increased levels of IL-8 in CLL plasma 
play a key role in priming neutrophils for NETs formation.
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Fig. 2  Plasma from CLL patients primes neutrophils from HD to 
release NETs. There were no differences in ROS production (a), 
elastase activity (b) or MPO activity (c) between neutrophils from 
CLL patients and HD donors (mean ± SEM, n = 6 or 10, ns not 
significant according to Kruskal–Wallis test). d Neutrophils from 
young HD were incubated with plasma from CLL patients or age-
matched HD prior to induction of NETosis. Results are shown as the 
mean ± SEM, n = 10. Significance was determined using Friedman 
test followed by Dunn’s multiple comparison posttest. e Representa-
tive images of NETotic neutrophils from HD activated in the presence 
of CLL plasma. Scale bar 15 µm. The percentage of cells showing 
loss of nuclear lobular shape and co-localization of elastase and DNA 
(arrow heads) are shown (mean ± SEM of 5 experiments). Signifi-
cance was determined using Friedman test followed by Dunn’s multi-
ple comparison posttest
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Fig. 3  IL-8 depletion impairs the priming activity of CLL plasma 
to release NETs. a IL-8 levels in plasma before (whole plasma) and 
after depletion with a specific Ab (n = 6). Significance was deter-
mined using Wilcoxon matched-pairs test. b Neutrophils from HD 
were incubated for 40 min with CLL plasma (IL-8 depleted or not), 
washed twice and stimulated with PMA for 4 h. Elastase activity and 
DNA concentration were quantified in supernatants (mean ± SEM, 
n = 10, Friedman test followed by Dunn’s multiple comparison post-
test). c Correlation between IL-8 levels in plasma from CLL patients 
and the capacity of PMA-activated neutrophils to release NETs. 
Spearman’s correlation coefficients are shown. d Addition of recom-
binant IL-8 (0.15 ng/ml) to HD plasma primes neutrophils to release 
NETs (mean ± SEM, n = 5)
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Plasma from CLL patients induces the up‑regulation 
of neutrophil CXCR2
Neutrophils co-express two different receptors that bind 
IL-8 with high affinity, the G protein-coupled transmem-
brane receptors CXCR1 and CXCR2 [31]. We asked 
whether plasma from CLL patients can modify the expres-
sion of these receptors and in that way regulate neutrophil 
activation by IL-8. Therefore, we incubated neutrophils 
from young HD with plasma from CLL patients or age-
matched HD for 40 min following the protocol described 
above. By flow cytometer, we observed that neutrophils 
exposed to plasma exhibited increased cell size as measured 
by forward light scatter (FSC-H), indicative of cell activa-
tion (Fig. 4a). Of note, plasma from CLL patients induced a 
higher increase in FSC-H compared to HD plasma. In line 
with these results, we found that CLL plasma increased the 
expression of CXCR2, while CXCR1 levels did not change 
(Fig. 4b, c). Although the factor(s) in plasma responsible 
for these effects remain unknown, it is conceivable that 
increased CXCR2 expression facilitated IL-8 priming of 
neutrophils to release NETS.
Fig. 4  Plasma from CLL 
patients induces the activa-
tion of neutrophils and the 
upregulation of CXCR2. 
Neutrophils from HD (n = 3) 
were incubated for 40 min with 
plasma from HD (n = 13), CLL 
patients (n = 13) or medium. 
After washing twice, cells were 
stained with anti-FITC-CXCR1 
mAb and PE-CXCR2 mAb and 
analyzed by flow cytometry. 
Shown are representative his-
tograms and mean ± SEM cor-
responding to: a cell size (FSC-
H), b CXCR1 and c CXCR2 
expression. Significance was 
determined using Friedman test 
followed by Dunn’s multiple 
comparison posttest
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NETs delay spontaneous apoptosis and increase the 
expression of activation markers in B cells from CLL 
patients
Increasing evidence indicates that NETs are able to modify 
the functional activity of different cell types. Thus, NETs 
can activate plasmacytoid dendritic cells leading to the 
secretion of IFNα [20] and can reduce the threshold of acti-
vation of CD4+ T lymphocytes through TCR crosslinking 
[32]. However, NETs not only exert stimulatory effects, but 
also can be cytotoxic against epithelial [33] and endothe-
lial cells [29]. Taking these data into account, we evaluated 
the effects of NETs on leukemic B cells from CLL patients. 
For these experiments we induced NETs with ionomycin 
instead of PMA because we were unable to completely 
eliminate PMA from NETs preparations despite exten-
sive washing of neutrophils one hour after challenge. On 
the contrary, we corroborated that NETs preparations were 
devoid of ionomycin as they were unable to induce calcium 
mobilization (supplementary figure 4).
As shown in Fig. 5a, incubation of B-CLL cells with 
NETs delayed spontaneous apoptosis and enhanced the 
expression of activation markers, such as costimulatory 
molecules (CD80 and CD86) and CD69. Comparable 
results were obtained with NETs induced by IL-8 plus 
LPS (Fig. 5b). To confirm that NETs were responsible 
for CLL-B cell activation, we also evaluated the effect of 
supernatants from non-stimulated neutrophils (Fig. 5b) and 
supernatants from neutrophils that had been fixed with 4% 
PFA immediately after challenge and therefore were una-
ble to generate NETs (Fig. 5a). None of these two types 
of control supernatants modified the expression of the 
activation markers. We found no differences in the effects 
induced by NETs from HD or CLL samples (not shown). 
Additional experiments showed that even in the presence of 
autologous plasma used as a potential source of degradative 
enzymes, NETs were able to protect and stimulate CLL-B 
cells (supplementary figure 5). By contrast, NETs did not 
delay spontaneous apoptosis of circulating B cells purified 
from HD samples (not shown).
Discussion
Despite the relevance of neutrophils in host defense, the 
current understanding of their role in CLL is incomplete 
compared to the phenotypical and functional characteriza-
tion of other immune cell populations. Neutrophil counts 
are generally normal or slightly reduced in untreated 
patients, and deep neutropenia is only associated with 
advanced disease due to bone marrow infiltration or mye-
losuppressive therapy [3–5]. While defective functions of 
neutrophils in CLL have been previously reported, data are 
scarce and contradictory particularly in regard to micro-
bicidal activity, which was found impaired in neutrophils 
from most CLL patients [34] or only from those with recur-
rent infections [35]. Reduced migration toward fMLP or 
C5a was also observed in CLL patients with a history of 
infections when compared to those without infections or 
HD [35]. In this work we have analyzed the capacity of 
neutrophils from CLL patients to form NETs, a function 
that has not been previously addressed in this pathology. 
Our results show that neutrophils from CLL patients are 
more prone to release NETs when stimulated in vitro com-
pared to neutrophils from age-matched HD. This different 
capacity was observed not only when neutrophils were 
challenged with potent pharmacological stimuli, as PMA or 
ionomycin, but also with relevant physiological stimuli as 
TNFα plus LPS.
Increased susceptibility to form NETs is not limited 
to neutrophils from CLL patients as it was also found in 
patients with rheumatoid arthritis, among other autoim-
mune diseases [36], and recently in individuals with type 
1 and type 2 diabetes [21]. The underlying causes for this 
tendency to form NETs are not completely understood and 
seem to be particular of each condition, i.e., high serum 
glucose levels in diabetes. In addition, it was reported in 
murine models that granulocyte colony-stimulating factor 
(G-CSF) released by tumor cells predisposes neutrophils to 
generate NETs and that this effect contributes to the pro-
thrombotic state observed in cancer [37]. In fact, NETs are 
essential for thrombosis in many contexts as they serve as 
structural scaffolding for entrapment and aggregation of 
platelets and erythrocytes [38]. Venous thromboembolism 
is a relatively frequent complication in patients with CLL 
[39, 40]. It is possible that the increased susceptibility of 
their neutrophils to release NETs may account, at least in 
part, for the higher risk of thrombotic events.
For most stimuli, including PMA and cytokines, NETs 
depend on the generation of ROS through the activation of 
NADPH oxidase [15]. Evidence indicates that ROS induce 
the release of elastase and MPO from the azurophilic gran-
ules in neutrophil cytoplasm allowing the translocation of 
these enzymes to the nucleus. Once in the nucleus, elastase 
partially degrades specific histones and MPO facilitates 
chromatin relaxation, leading to the extrusion of NETs 
[27]. We did not find differences in the levels of ROS pro-
duced by PMA-activated neutrophils from CLL patients or 
HD, in agreement with a previous report [41]. We neither 
found differences in the enzymatic activity of elastase or 
MPO that could explain the increased capacity of neutro-
phils from CLL patients to release NETs. Since a variety 
of cytokines, growth factors or extrinsic conditions such as 
high glucose levels increases susceptibility of neutrophils 
to release NETs, we looked for soluble factors in plasma 
of CLL patients capable of priming neutrophils. We were 
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able to identify IL-8 as one of these factors. We found that 
IL-8 levels were significantly increased in plasma from 
the majority of the patients evaluated and, more impor-
tantly, that IL-8 depletion markedly decreased the priming 
activity of CLL plasma. Moreover, we found that CLL 
plasma increased the expression of neutrophil CXCR2 
and in this way might facilitate IL-8 priming to NETosis. 
Finally, further evidence for the key role of IL-8 was the 
Fig. 5  NETs delay spontaneous apoptosis and increase the expres-
sion of activation markers in CLL-B cells. a Shown are representative 
dot plots and the percentage of Annexin-V-positive cells after 48 h 
with or without ionomycin-induced NETs. Significance was deter-
mined using Wilcoxon matched-pairs test, n = 13. b Expression of 
activation markers in CLL cells incubated with PMA-induced NETs, 
supernatants from PFA-fixed neutrophils or medium (mean ± SEM, 
n = 6–9 CLL). Significance was determined using Friedman test 
followed by Dunn’s multiple comparison posttest. c Apoptosis and 
activation markers in CLL cells incubated with medium, superna-
tants from unstimulated neutrophils or NETs induced by IL-8 + LPS 
(mean ± SEM, n = 6)
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clear correlation between the levels of plasmatic IL-8 and 
the capacity of neutrophils to generate NETs. Other soluble 
factors that favor NETs release, such as TNFα, IL-1β [17, 
28], or HMGB1 [16], have been reported to be increased 
in plasma of a proportion of CLL patients [30, 42]. While 
the plasmatic levels of TNFα in our patient cohort were not 
high enough to prime neutrophils of HD to release NETs 
(data not shown), the presence of other NET-priming fac-
tors remains to be evaluated.
A relevant finding of our study was the positive effects 
exerted by NETs on leukemic B cells that led to a delay 
in spontaneous apoptosis in vitro and the upregulation of 
activation markers. Both stimulating and deleterious effects 
of NETs have been reported depending on the experimen-
tal model analyzed. Endothelial damage by NETs was con-
sistently observed in vitro [29] and in vivo [43], though the 
mechanism responsible for cytotoxicity remains unclear. 
An intact DNA lattice structure is required since degrada-
tion of NETs with DNAse protects endothelial cells from 
death, suggesting that proteases and antimicrobial pep-
tides are not sufficient to induce damage unless they are 
concentrated in the chromatin backbone [29]. Instead of 
inducing cell death, exposure of plasmacytoid dendritic 
cells to NETs acts as a potent stimulus for IFNα release 
through the interaction of self-DNA with TLR-9 [20]. In 
atherosclerosis, NETs prime macrophages for IL-1β release 
upon activation with cholesterol crystals. In this case, not 
only DNA but also TLR-2 and TLR-4 ligands in NETs are 
required for optimal production of IL-1β [18]. Although 
we currently do not know through which receptor(s) leu-
kemic B cells respond to NETs, preliminary, unpublished 
data indicate that degradation of DNA does not impair the 
protective effects of NETs, suggesting that TLR-9 or cyto-
plasmic DNA receptors might not be involved.
NETs were initially described as efficient weapons to 
capture and destroy extracellular pathogens, and therefore 
the increased capacity of neutrophils from CLL patients to 
release NETs should contribute to clear bacteria. Yet this 
seems not to be the case because infectious complications 
are still the major cause of morbidity and mortality in CLL 
patients, with the respiratory tract being the most common 
site of bacterial infection [5, 44]. However, the formation of 
NETs in the respiratory tract could be detrimental instead 
of beneficial, as was shown in bacterial pneumonia second-
ary to influenza infection [45] and, recently, in lower res-
piratory tract disease caused by respiratory syncytial virus 
[46]. In these cases, the abundant NETs release contributes 
to inflammation and airway obstruction. It is now clear that 
NETs exert both protective and harmful effects, depend-
ing on their concentration, the place where they are formed 
and the capacity of the organism to properly remove them. 
In fact, the persistence of NETs may represent a source of 
autoantigens and immunostimulatory molecules involved 
in the development of many autoimmune diseases. In the 
context of CLL, at least some of NETs components, i.e., 
histones, actin or DNA, might play a role in the initiation 
or progression of the disease as they can be recognized 
through the B cell receptor of a proportion of CLL clones 
[47]. Of note, NETs in the form of extracellular MPO 
threads have been detected in close contact with leukemic 
B cells in spleen biopsies from CLL patients [48]. This is 
not a common feature of all B malignancies since infil-
trated neutrophils in diffuse large B cell lymphoma samples 
showed no signs of NET formation. Therefore, it seems 
reasonable to propose that neutrophils migrated to lym-
phoid tissues during infection or under sterile inflamma-
tion in CLL patients would be prone to release NETs which 
could favor leukemic cell survival and activation.
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